Pay in 4 interest-free payments of $7.38 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
For upcoming obesity drugs, key areas of competition are expected to include reducing the number of annual injections, shifting to oral medications, and lowering side effects, muscle loss and rebound weight gain
Lilly raised full-year guidance to $63.0-63.5 billion in revenue and $23.00-23.70 in non-GAAP EPS
Treatment is HSA/FSA eligible, and your price stays flat regardless of dose escalation
Exploring Obesity Clinical Trials Obesity clinical trials are research studies designed to evaluate new treatments, medications, or behavioral strategies for managing and reducing excess weight
US$ 21.76
US$ 29.84
US$ 20.73
US$ 28.77
US$ 21.65
US$ 26.04
